- Home
- MMA vs BFRI Comparison
MMA vs BFRI Comparison
Compare MMA & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | BFRI |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 12.2M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MMA | BFRI |
|---|---|---|
| Price | $0.30 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 2.4M | 259.0K |
| Earning Date | 10-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,705,000.00 |
| Revenue This Year | N/A | $10.65 |
| Revenue Next Year | N/A | $15.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $0.23 | $0.57 |
| 52 Week High | $1.65 | $1.66 |
Technical Indicators
Market Signals| Indicator | MMA | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 30.04 |
| Support Level | $0.23 | $0.77 |
| Resistance Level | $0.44 | $0.97 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 37.09 | 8.43 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.